Abstract:Ewing's sarcoma (EWS) is an aggressive bone and soft-tissue cancer, characterized by a hallmark fusion oncoprotein comprising the amino terminus of a FET gene and the carboxy terminus of an ETS gene, most commonly (85%), the EWSR1-FLI1 t (11,22) fusion.TK-216 is a first-in-class EWSR1-FLI1 inhibitor currently in phase II clinical trials for EWS. Although TK-216 was designed to target the fusion protein interaction directly, it has demonstrated limited efficacy as a monotherapy. Thus, more effective TK-216 combination therapies are needed. We have used genome wide Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Knockout screening in EWS cells treated with TK-216 to identify novel synthetic lethality. We have identified 97 genes whose deletion potentially enhances the action of TK-216 in EWS cells. We have also identified several druggable targets, such as USP9X and the oxidative phosphorylation (OXPHOS) pathway as synthetic lethal interactions for TK-216. USP9X is known to deubiquitinate and stabilize the EWS-FLI1 fusion protein. USP9X and EWS-FLI1 protein expression levels were found to be positively correlated in EWS clinical specimens. USP9X siRNA-mediated gene silencing reduced EWS cell viability. Most importantly, USP9X siRNA-mediated gene silencing sensitized EWS cells to TK-216 treatment. In addition, inhibition of USP9X with a small-molecule inhibitor WP1130, led to significant cell death in EWS alone and in combination with TK-216 with wide therapeutic indices. The molecular mechanism of synergy and in vivo efficacy of the novel TK-216 combination will be determined in our study for future clinical translation. Citation Format: Daenikka Ravindrarajah, Sukriti Krishan, Kayleen Simpson, Twishi Gulati, Belamy B. Cheung, Glenn M. Marshall. Using genome-wide CRISPR screening to develop novel combination therapies for high-risk Ewing's sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1080.

Screening of HLA-A2.1-restricted CTL epitopes derived from Ewing's sarcoma EWS-FLI1 fusion protein by using molecular simulation

Identification of predicted epitopes of HLA-A * 0201-restricted cytotoxic T lymphocytes derived from human papillomavirus type 11 E7 antigen

Screening of HLA-A2 Restricted CTL Epitopes Using Molecular Simulation

A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing’s sarcoma cells, interacts with the EWS-FLI1 and partner proteins

Computer aided screening of tyrosinase related protein-2 (180 similar to 188) mimotope

Identification of a Common HLA-A*0201-restricted Epitope among SSX Family Members by Mimicking Altered Peptide Ligands Strategy.

Prediction of HLA-A2.1 Restricted CTL Epitope of SSX Gene Family and Affinity Assay of These Epitopes with MHC- Ⅰ Molecule

Prediction, Synthesis and Identification of HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes of the Tumor Antigen MAGE-n

Molecular Field Analysis on HLA-A*0201 Restricted CTL Epitope

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28

Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue*

Prediction of HLA-A*0201 Restricted Cytotoxic T Lymphocyte Epitopes Based on High-Dimensional Descriptor Nonlinear Screening

Prediction and identification of HLA-A0201 restricted CTL epitopes derived from human telomerase reverse transcriptase antigen

Abstract 1080: Using genome-wide CRISPR screening to develop novel combination therapies for high-risk Ewing's sarcoma

Two Novel Squamous Cell Carcinoma Antigen-Derived HLA-A*0201-binding Peptides Induce in Vitro and in Vivo CD8+ Cytotoxic T Lymphocyte Responses.

Prediction and Identification of HLA-A*0201-restricted Epitopes from Leukemia-Associated Protein MLAA-22 Which Elicit Cytotoxic T Lymphocytes

The gene diagnosis of Ewing's sarcoma and synovial sarcoma

Rational Optimization of Tumor Epitopes Using in Silico Analysis-Assisted Substitution of Tcr Contact Residues

Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells

Expression and Diagnostic Value of the EWS-ATF1 Fusion Gene in Clear Cell Sarcoma